Gainers

• XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 9.3% to $0.85 during Tuesday's after-market session. The company's market cap stands at $7.1 million.
• Akari Therapeutics (NASDAQ:AKTX) shares increased by 8.27% to $0.27. The market value of their outstanding shares is at $9.4 million.
• Trinity Biotech (NASDAQ:TRIB) stock moved upwards by 7.81% to $1.38. The company's market cap stands at $17.1 million.
• Adagio Medical Holdings (NASDAQ:ADGM) shares moved upwards by 5.0% to $1.05. The company's market cap stands at $23.0 million.
• Theriva Biologics (AMEX:TOVX) shares increased by 3.72% to $0.21. The market value of their outstanding shares is at $6.5 million.
• Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 3.08% to $0.33. The market value of their outstanding shares is at $67.8 million.

Losers

• Bone Biologics (NASDAQ:BBLG) stock declined by 7.7% to $1.8 during Tuesday's after-market session. The company's market cap stands at $3.3 million.
• Cypherpunk Technologies (NASDAQ:CYPH) stock decreased by 4.24% to $1.13. The company's market cap stands at $62.3 million.
• EUDA Health Holdings (NASDAQ:EUDA) shares decreased by 2.61% to $1.87. The market value of their outstanding shares is at $51.4 million.
• Pomdoctor (NASDAQ:POM) shares decreased by 2.43% to $0.34. The company's market cap stands at $31.8 million.
• Allogene Therapeutics (NASDAQ:ALLO) shares decreased by 2.21% to $1.33. The company's market cap stands at $330.3 million.
• Inspire Veterinary (NASDAQ:IVP) stock fell 1.99% to $0.04. The company's market cap stands at $1.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.